Literature DB >> 23381464

Monitoring target specific anticoagulants.

Barbara A Konkle1.   

Abstract

New, target specific, oral anticoagulants have been shown to be safe and effective in prevention and treatment of thromboembolism without laboratory monitoring. However, clinical use of the drugs dabigatran, rivaroxaban, and apixaban requires laboratory measurement of their anticoagulant effect in specific clinical situations. This paper reviews the data available on use of screening and specialized testing to measure the anticoagulant effect and drug levels in patients prescribed these medications. Their effect on other coagulation assays is also reviewed.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23381464     DOI： 10.1007/s11239-013-0880-5

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


  21 in total

1.  Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.

Authors:  Yu Chen Barrett; Zhaoqing Wang; Charles Frost; Andrew Shenker
Journal:  Thromb Haemost       Date:  2010-10-26       Impact factor: 5.249

2.  WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING.

Authors:  E W DAVIE; O D RATNOFF
Journal:  Science       Date:  1964-09-18       Impact factor: 47.728

3.  Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.

Authors:  Meyer Michel Samama; Jean-Luc Martinoli; Léna LeFlem; Céline Guinet; Geneviève Plu-Bureau; François Depasse; Elisabeth Perzborn
Journal:  Thromb Haemost       Date:  2010-02-02       Impact factor: 5.249

4.  Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.

Authors:  Trevor Baglin; David Keeling; Steve Kitchen
Journal:  Br J Haematol       Date:  2012-09-13       Impact factor: 6.998

Review 5.  Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

Authors:  Joanne van Ryn; Joachim Stangier; Sebastian Haertter; Karl-Heinz Liesenfeld; Wolfgang Wienen; Martin Feuring; Andreas Clemens
Journal:  Thromb Haemost       Date:  2010-03-29       Impact factor: 5.249

Review 6.  Coagulation assays and anticoagulant monitoring.

Authors:  Dorothy M Adcock Funk
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

7.  Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.

Authors:  Dagmar Kubitza; Michael Becka; Barbara Voith; Michael Zuehlsdorf; Georg Wensing
Journal:  Clin Pharmacol Ther       Date:  2005-10       Impact factor: 6.875

8.  Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.

Authors:  A Hillarp; F Baghaei; I Fagerberg Blixter; K M Gustafsson; L Stigendal; M Sten-Linder; K Strandberg; T L Lindahl
Journal:  J Thromb Haemost       Date:  2011-01       Impact factor: 5.824

9.  Monitoring direct thrombin inhibitors with a plasma diluted thrombin time.

Authors:  Jason E Love; Chris Ferrell; Wayne L Chandler
Journal:  Thromb Haemost       Date:  2007-07       Impact factor: 5.249

10.  The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.

Authors:  Joachim Stangier; Karin Rathgen; Hildegard Stähle; Dietmar Gansser; Willy Roth
Journal:  Br J Clin Pharmacol       Date:  2007-05-15       Impact factor: 4.335
View more
  4 in total

1.  [Monitoring of NOAC].

Authors:  R B Zotz; L Weißbach
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-01-12       Impact factor: 0.840

2.  Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation: a tentative approach based on routine laboratory tests.

Authors:  Giuseppe Lippi; Diego Ardissino; Roberto Quintavalla; Gianfranco Cervellin
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

Review 3.  New oral anticoagulants and the cancer patient.

Authors:  Nicholas J Short; Jean M Connors
Journal:  Oncologist       Date:  2013-12-06

Review 4.  Spontaneous Intracerebral Hemorrhage: Management.

Authors:  Jun Yup Kim; Hee-Joon Bae
Journal:  J Stroke       Date:  2016-01-31       Impact factor: 6.967
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.